What is HC Wainwright’s Estimate for AVXL Q1 Earnings?

Anavex Life Sciences Corp. (NASDAQ:AVXL) – Research analysts at HC Wainwright issued their Q1 2027 earnings per share (EPS) estimates for shares of Anavex Life Sciences in a research note issued to investors on Tuesday, February 10th. HC Wainwright analyst R. Selvaraju expects that the biotechnology company will post earnings per share of ($0.12) for the quarter. HC Wainwright has a “Buy” rating and a $20.00 price target on the stock. The consensus estimate for Anavex Life Sciences’ current full-year earnings is ($0.69) per share. HC Wainwright also issued estimates for Anavex Life Sciences’ Q2 2027 earnings at ($0.13) EPS, Q3 2027 earnings at ($0.14) EPS, Q4 2027 earnings at ($0.15) EPS and FY2027 earnings at ($0.55) EPS.

Anavex Life Sciences (NASDAQ:AVXL) last announced its earnings results on Monday, February 9th. The biotechnology company reported ($0.06) EPS for the quarter, topping the consensus estimate of ($0.10) by $0.04.

A number of other brokerages have also commented on AVXL. Weiss Ratings reiterated a “sell (d-)” rating on shares of Anavex Life Sciences in a research report on Monday, December 29th. D. Boral Capital reaffirmed a “buy” rating and set a $24.00 price target on shares of Anavex Life Sciences in a research report on Monday. Finally, Jones Trading lowered shares of Anavex Life Sciences from a “buy” rating to a “hold” rating in a research note on Friday, October 24th. Two investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Anavex Life Sciences presently has a consensus rating of “Hold” and an average price target of $22.00.

Anavex Life Sciences Price Performance

AVXL opened at $3.92 on Wednesday. The stock has a market capitalization of $363.27 million, a P/E ratio of -8.52 and a beta of 1.21. The company’s 50 day simple moving average is $4.27 and its 200-day simple moving average is $6.92. Anavex Life Sciences has a one year low of $2.86 and a one year high of $13.99.

Hedge Funds Weigh In On Anavex Life Sciences

A number of hedge funds have recently bought and sold shares of AVXL. Renaissance Technologies LLC acquired a new stake in shares of Anavex Life Sciences in the fourth quarter valued at approximately $91,000. Dimensional Fund Advisors LP acquired a new position in Anavex Life Sciences in the fourth quarter valued at about $97,000. Federated Hermes Inc. bought a new stake in Anavex Life Sciences during the fourth quarter worth about $1,310,000. Bank of Montreal Can grew its stake in Anavex Life Sciences by 41.3% during the fourth quarter. Bank of Montreal Can now owns 32,440 shares of the biotechnology company’s stock worth $115,000 after buying an additional 9,485 shares in the last quarter. Finally, Alps Advisors Inc. grew its stake in Anavex Life Sciences by 90.0% during the fourth quarter. Alps Advisors Inc. now owns 73,361 shares of the biotechnology company’s stock worth $261,000 after buying an additional 34,755 shares in the last quarter. 31.55% of the stock is owned by institutional investors.

Key Stories Impacting Anavex Life Sciences

Here are the key news stories impacting Anavex Life Sciences this week:

• Positive Sentiment: HC Wainwright raised multiple 2026 EPS estimates (Q2, Q3, Q4 and FY2026) and now models FY2026 at a smaller loss, while reiterating a “Buy” rating and a $20.00 price target — a material positive for sentiment and valuation expectations. Read More.
• Positive Sentiment: Zacks upgraded Anavex to a Zacks Rank #2 (Buy), signaling growing optimism about its earnings prospects and placing additional buy‑side attention on the ticker. Read More.
• Positive Sentiment: HC Wainwright also published multi‑quarter and FY2027 EPS projections (new estimates for Q1–Q4 2027 and FY2027) alongside its coverage, reinforcing analyst engagement and a bullish $20 target. Read More.
• Neutral Sentiment: Analyst/sector comparison pieces note how AVXL is performing vs. medical peers year‑to‑date — useful for relative performance context but not an immediate catalyst. Read More.
• Neutral Sentiment: Short‑interest data reported for early February shows 0 shares and anomalous “NaN” increases — this appears to be a reporting/data issue rather than a real build in short pressure, so it’s not currently informative for direction. (Internal short‑interest entries 2/11–2/12)

Anavex Life Sciences Company Profile

Anavex Life Sciences Corp is a clinical‐stage biopharmaceutical company focused on the development of novel therapeutics for central nervous system (CNS) disorders. The company applies a proprietary drug discovery platform that targets sigma‐1 and muscarinic receptors to modulate cellular stress pathways and support neuronal function. Headquartered in New York City, Anavex is dedicated to advancing treatments for neurodegenerative and neurodevelopmental diseases with high unmet medical need.

The company’s lead product candidate, blarcamesine (ANAVEX2‐73), is a small‐molecule activator of the sigma‐1 receptor currently being evaluated in clinical trials for Alzheimer’s disease and Parkinson’s disease dementia.